Serum Kallistatin as a Biomarker of Sepsis and Mortality in Geriatric Patients with Acute Kidney Injury Kalistatin u serumu kao biomarker za sepsu i smrtnost kod gerijatrijskih bolesnika s akutnim oštećenjem bubrega
Acta Clinica Croatica, cilt.65, sa.1, ss.12-21, 2026 (SCI-Expanded, Scopus)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 65 Sayı: 1
- Basım Tarihi: 2026
- Doi Numarası: 10.20471/acc.2026.65.01.02
- Dergi Adı: Acta Clinica Croatica
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, EMBASE, MEDLINE, Directory of Open Access Journals
- Sayfa Sayıları: ss.12-21
- Anahtar Kelimeler: Acute kidney injury, Geriatric patients, Elderly, Kallistatin, Brain natriuretic peptide, Cardiovascular biomarkers, Sepsis, Mortality
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Kallistatin has beneficial effects on cardiorenal injury by inhibiting oxidative stress, angiogenesis and inflammation. However, the role in geriatric patients with acute kidney injury (AKI) has not been investigated in clinical studies. The aim of this study was to evaluate the relationship among kallistatin, cardiovascular biomarkers and mortality in geriatric patients with AKI and infection. In this observational, longitudinal study, 104 geriatric patients (age >65 years) with AKI were included. Serum kallistatin, NT-proBNP, troponin I and CK-MB were measured at first admission. Patients were evaluated according to the infection and/or sepsis status. The mean age of patients was 80±7.0 years. Twenty-five (24%) AKI patients died during hospitalization. The nonsurvivor geriatric patients with AKI were significantly older than survivors. Serum albumin and kallistatin levels were significantly lower, however, NT-proBNP and serum urea levels were significantly higher in nonsurvivors compared to survivors. Serum kallistatin levels in patients with sepsis were lower than in those without sepsis (10.2±3.9 vs. 17.4±2.5; p<0.001). The mortality rate was 4.6 higher in septic patients (46% vs. 10%; p<0.001). Serum kallistatin (Exp(B): 0.83 (0.73-0.94; p<0.01) and NT-proBNP (Exp(B): 1.001 (1.001-1.002); p<0.05) were independently associated with mortality. Serum kallistatin and NT-proBNP levels were associated with mortality of geriatric patients with AKI. In addition, the presence of sepsis in AKI may be responsible for low serum kallistatin levels. Large-scale studies are needed to clarify this issue.